4/A: Aclaris CBO Amends Form 4 for RSU Vesting, Tax Withholding

Aclaris Therapeutics' Chief Business Officer, James Loerop, filed an amended Form 4 to correct previously reported RSU vesting and tax withholding transactions.

Summary

• James Loerop, Chief Business Officer of Aclaris Therapeutics, Inc., filed an amended Form 4 to correct an error in a previous filing.
• The amendment clarifies transactions that occurred on February 1, 2026, which were erroneously reported as February 1, 2025, in the original filing.
• On February 1, 2026, Mr. Loerop acquired a total of 33,500 shares of common stock through the vesting and settlement of restricted stock units (RSUs).
• These acquisitions included 11,250 shares from RSUs granted on February 1, 2022, 7,500 shares from RSUs granted on February 1, 2023, and 14,750 shares from RSUs granted on February 1, 2024.
• Concurrently, 10,686 shares of common stock were disposed of at a price of $3.51 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these reported transactions, Mr. Loerop's direct beneficial ownership of common stock is 177,322 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It is a routine disclosure of executive compensation and a correction of a clerical error, neither of which significantly impacts the company's operational or financial standing.

Positives

• The Chief Business Officer continues to hold a significant number of shares (177,322), indicating alignment with shareholder interests.
• The vesting of restricted stock units represents a scheduled compensation event, reflecting the executive's continued service to the company.

Negatives

• A portion of the vested shares (10,686 shares) was sold to cover tax liabilities, which is a common practice but reduces the executive's direct ownership slightly.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider transaction filings like Form 4/A are routine disclosures for executive compensation and do not typically reflect broader industry trends or strategic shifts. They primarily provide transparency into individual executive stock movements.

Stakeholder Impact

• Shareholders: Provides transparency regarding executive compensation and share ownership, which is generally positive for corporate governance. The correction ensures accurate public records.
• Management: The Chief Business Officer's compensation structure (RSUs) is clarified.

Key Dates

Recommendation

This Form 4/A filing is a routine disclosure of executive stock transactions related to RSU vesting and tax withholding, along with a correction of a clerical error. It does not contain information that would fundamentally alter the investment thesis for Aclaris Therapeutics, Inc. Therefore, a 'hold' recommendation is appropriate as it provides no new material information to warrant a change in investment position.

Keywords

Aclaris Therapeutics, ACRS, James Loerop, Chief Business Officer, Form 4/A, SEC filing, insider transaction, restricted stock units, RSU vesting, tax withholding, beneficial ownership